Imaging Core

成像核心

• 批准号: 9921661
• 负责人: Richard E. Carson
• 金额: $ 34.71万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9921661
• 关键词: Alzheimer' s Disease; Alzheimer' s disease pathology; Alzheimer’s disease biomarker; Amyloid; Atlases; Autopsy; Behavior; Behavioral Model; Binding; Biological Markers; Brain; Clinical; Clinical Research; Clinical Trials; Cognitive; Data; Data Analyses; Data Set; Development; Dimensions; Disease Pathway; Disease Progression; Functional Magnetic Resonance Imaging; Functional disorder; Future; Goals; Hippocampus (Brain); Human; Image; Image Analysis; Imaging Device; Imaging technology; Individual; Infrastructure; Lead; Link; Magnetic Resonance; Magnetic Resonance Imaging; Measurable; Measures; Methodology; Methods; Modality; Modeling; Multimodal Imaging; NIH Program Announcements; Nerve Degeneration; Noise; Paper; Participant; Patients; Pattern; Phenotype; Positron-Emission Tomography; Principal Investigator; Radiation Dose Unit; Research; Research Personnel; Resolution; Resources; Scanning; Statistical Data Interpretation; Statistical Models; Structure; Study Subject; Synapses; System; Techniques; Tracer; Training; Work; aged; analytical method; base; connectome; connectome based predictive modeling; data management; deep learning; density; experience; fluorodeoxyglucose; glucose metabolism; human imaging; human subject; imaging biomarker; imaging study; in vivo; in vivo imaging; innovation; mild cognitive impairment; multimodal data; multimodality; neuroimaging; neuropathology; next generation; nonhuman primate; novel; novel strategies; pre-clinical; programs; research study; success; tau Proteins

Project Summary: Yale ADRC Imaging Core The Yale Alzheimer Disease Research Center has the overall goal to advance understanding and treatment of Alzheimer’s disease (AD). This effort requires integration of a wide array of core functions, including Clinical, Neuropathology, and Neuroimaging. Human imaging studies allow for the development of imaging biomarkers of AD, characterization of the temporal sequence of AD pathology, and lead to better assignment of patients to clinical research studies and clinical trials. Imaging is a major strength at Yale, as exemplified by the breadth and depth offered by the Yale PET Center and the Yale Magnetic Resonance Research Center (MRRC). In the PET Center, an example of recent significant work is the introduction of PET synaptic imaging with the SV2A tracer 11C-UCB-J. In MRI, the Yale MRRC has generated numerous novel methods to characterize an individual’s functional connectome and relate the functional organization to behavior and clinical variables Overall, these two Centers develop cutting edge imaging technologies and apply these techniques to answer important clinical questions. By creating this Yale ADRC Imaging Core (YAIC), we leverage the vast experience of Yale’s imaging strengths to provide state-of-the-art acquisition and analysis of imaging data and to focus on the development of novel approaches to AD. The YAIC will provide a common infrastructure for acquisition, processing, and analysis of multimodal imaging data, to support and train AD investigators and develop the next generation of imaging tools. The current and future methods will be applied to ongoing imaging studies to acquire a rich, multi-faceted and multi-modality dataset in human subjects. In addition, the translational component of this program examines the utility of nonhuman primates (NHPs) as a model for human AD. The Imaging Core will perform the following specific aims: Aim 1: To develop and optimize PET image and data analysis strategies to facilitate within- and between-subject comparisons. Multi-tracer within- subject correlations are important, involving amyloid, tau, synaptic density, and glucose metabolism. Aim 2: To enhance our MR-based functional connectome modeling to better functionally phenotype patients and link brain to behavior. This approach provides a functional profile for each individual while localizing the networks and revealing the network organizing principles supporting these functions. Aim 3: To develop and enrich multi- modality analyses between PET and fMRI for within- and between-subject studies. The combination of fMRI- based connectivity with the regional patterns of neurodegeneration measurable with PET provides an ideal opportunity for understanding the pathways of disease progression. Aim 4: To extend the methodologies developed for human analysis to NHP data. Ongoing studies in aged NHPs are being performed, providing the opportunity to compare in vivo PET and MR imaging with post-mortem measures provided by the Neuropathology Core.

项目概要：Yale ADRC成像核心 耶鲁大学阿尔茨海默病研究中心的总体目标是促进对阿尔茨海默病的理解和治疗。 阿尔茨海默病（AD）。这项工作需要整合广泛的核心功能，包括临床， 神经病理学和神经影像学。人类成像研究允许开发成像生物标志物 的AD，表征AD病理学的时间序列，并导致更好地分配患者， 临床研究和临床试验。影像学是耶鲁大学的一个主要优势， 耶鲁PET中心和耶鲁磁共振研究中心（MRRC）提供的深度和深度。在 PET中心，最近的一个重要工作的例子是引入PET突触成像与SV 2A 示踪剂11 C-UCB-J。在MRI中，Yale MRRC已经产生了许多新的方法来表征 个体的功能连接体，并将功能组织与行为和临床变量联系起来 总的来说，这两个中心开发尖端的成像技术，并应用这些技术来回答 重要的临床问题通过创建这个耶鲁ADRC成像核心（YAIC），我们利用了 耶鲁大学的成像优势的经验，提供最先进的采集和分析成像数据， 专注于开发治疗AD的新方法。YAIC将提供一个通用的基础设施， 采集、处理和分析多模态成像数据，以支持和培训AD研究者， 开发下一代成像工具。目前和未来的方法将适用于正在进行的 成像研究，以获取人类受试者的丰富、多方面和多模态数据集。此外该 该计划的翻译部分检查了非人灵长类动物（NHP）作为模型的实用性， 人类AD。成像核心将执行以下具体目标：目标1：开发和优化PET 图像和数据分析策略，以促进受试者内和受试者之间的比较。多示踪剂内- 受试者相关性是重要的，涉及淀粉样蛋白、tau、突触密度和葡萄糖代谢。目标2： 增强我们基于MR的功能性连接体建模，以更好地功能性表型患者， 大脑到行为这种方法在定位网络的同时为每个人提供了功能配置文件 并揭示了支持这些功能的网络组织原则。目标3：发展和丰富多种 PET和fMRI之间的模态分析，用于受试者内和受试者间研究。结合功能性磁共振成像- 基于与PET可测量的神经退行性变的区域模式的连接提供了一个理想的 了解疾病进展途径的机会。目标4：推广方法 为人类分析NHP数据而开发。正在对老年NHP进行研究， 有机会比较体内PET和MR成像与尸检措施提供的 神经病理学核心。